RECRUITING

Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery

Talk to us

Conditions

ShiveringDose Finding StudyCesarean DeliveryDexmedetomidineDosing

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.

Official Title

Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose

Quick Facts

Study Start:2021-09-21
Study Completion:2025-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04730609

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Women presenting for planned cesarean delivery.
  2. * American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
  3. * Singleton gestation in the 3rd trimester (28-42 weeks gestation).
  4. * Spinal anesthesia technique Women presenting for planned cesarean delivery.
  5. * American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.
  6. * Singleton gestation in the 3rd trimester (28-42 weeks gestation).
  7. * Spinal anesthesia technique.
  1. * Any contraindication to spinal anesthesia technique.
  2. * Allergy or intolerance to dexmedetomidine or clonidine.
  3. * Oral temperature \< 36° Celsius prior to procedure.
  4. * Unable to give personal consent.
  5. * PPROM or concern for infection (e.g., chorioamnionitis).
  6. * Conversion to General Anesthesia prior to randomization.
  7. * Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.

Contacts and Locations

Study Contact

Hans P Sviggum, MD
CONTACT
507-293-1169
sviggum.hans@mayo.edu

Principal Investigator

Hans Sviggum, MD
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Hans Sviggum, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-21
Study Completion Date2025-08

Study Record Updates

Study Start Date2021-09-21
Study Completion Date2025-08

Terms related to this study

Keywords Provided by Researchers

  • Shivering
  • Cesarean Delivery
  • Dexmedetomidine
  • Dosing

Additional Relevant MeSH Terms

  • Shivering
  • Dose Finding Study